简单改变靶向药用法，效果居然好这么多( 三 ) 文|菠萝惊艳的三年总生存率在最近结束

正因为如此， ALK突变患者使用一种二代靶向药耐药后，仍可能从另一个二代靶向药中获益。比如，用阿来替尼后耐药的患者，如果基因检测发现是因为ALK基因的I1171N突变，那用塞瑞替尼还有可能使病症得到进一步治疗。反之亦然。
另一方面，要看患者对不同副作用的耐受度。
塞瑞替尼的副作用主要在胃肠道，比如腹泻，恶心等，阿来替尼则是肝脏和肾脏问题，表现为胆红素上升，血肌酐升高等。患者本来就有胃肠道或肝肾问题，医生可能会优先推荐对应副作用更小的药物。
【简单改变靶向药用法，效果居然好这么多】特别高兴看到塞瑞替尼优秀的最新数据，参与的科学家们功不可没，肯定都很有成就感。
随着越来越多靶向新药的出现，未来ALK融合突变肺癌患者很多都可能活到5年，甚至7年以上。对于他们而言，癌症可能会变成一种慢性病，这对增强患者治疗信念、提高生存质量都是一种里程碑式的转变。相信会有更多的好消息，让“钻石”更加闪亮。
致敬生命！
*本文旨在科普癌症新药背后的科学，不是药物宣传资料，更不是治疗方案推荐。如需获得疾病治疗方案指导，请前往正规医院就诊。
参考文献：
[1] ASCEND-8: A Randomized Phase 1 Study ofCeritinib, 450 Mg or 600 Mg, Taken With a Low-Fat Meal Versus 750 Mg in FastedState in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged MetastaticNon-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017 Sep;12(9):1357-1367.
[2]I1171 Missense Mutation (ParticularlyI1171N) Is a Common Resistance Mutation in ALK-positive NSCLC Patients Who HaveProgressive Disease While on Alectinib and Is Sensitive to Ceritinib. LungCancer. 2015 May;88(2):231-4.
[3]Targeting ALK: Precision Medicine Takes onDrug Resistance. Cancer Discovery. 2017 Feb;7(2):137-155.
[4]Comparative Efficacy of Ceritinib andCrizotinib as Initial ALK-Targeted Therapies in Previously Treated AdvancedNSCLC: An Adjusted Comparison with External Controls. J Thorac Oncol. 2016Sep;11(9):1550-7.
[5]First-line ceritinib versus platinum-basedchemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4):a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929.
[6]Ceritinib in ALK-rearranged non-small-celllung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97
[7]Multicenter Phase II Study of Whole-Bodyand Intracranial Activity With Ceritinib in Patients With ALK-RearrangedNon-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib:Results From ASCEND-2. J Clin Oncol. 2016 Aug 20;34(24):2866-73.
[8]First-line ceritinib versus platinum-basedchemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4):a randomised, open-label, phase 3 study. Lancet. 2017 Mar 4;389(10072):917-929.
[9]Ceritinib versus chemotherapy in patientswith ALK-rearranged non-small-cell lung cancer previously given chemotherapyand crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2017 Jul;18(7):874-886.